Macular Degeneration Watch Time: 40 mins

touchCONGRESS Will a scientific breakthrough translate into clinical benefits in nAMD? Highlights from EURETINA 2019

Stay up to date with the latest developments in the management and treatment of patients with nAMD with our expert summary from the 19th EURETINA Congress in Paris, France, 5–8 September 2019.

Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review key data from EURETINA 2019

Part 2: Choose from leading experts who discuss what data findings mean for global and regional practice

  • Part 1: Webinar
Next Chapter
Introduction
Why is retinal fluid important as a marker of disease activity in patients with nAMD?
How can the burden of nAMD be reduced, and patient adherence and QoL improved?
What are the real-life clinical unmet needs? Does size matter when considering treatment options?
Video Player Controls:
 
Leave Feedback
Overview

Watch Prof. Anat Loewenstein reviewing the most important emerging data presented at the 19th EURETINA Congress and discussing their potential impact for addressing real-life clinical unmet needs in nAMD, including:

  • Why is retinal fluid important as a marker of disease activity in patients with nAMD? Focus on the rationale for and evidence to support using retinal fluid as a marker
  • How could the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes
  • What are the potential benefits of a smaller-size anti-VEGF therapy on dosing? Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes
About Prof. Anat Loewenstein

Prof. Anat Loewenstein is the Chair of the Department of Ophthalmology, Tel Aviv Medical Centre and Professor of Ophthalmology and Vice Dean, Tel Aviv University. An expert in retinal toxicity with a strong research interest in the early detection of retinal disease, Prof. Loewenstein has served as the principal investigator of many clinical trials of anti-VEGF agents and steroid implants for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Prof. Loewenstein is currently the General Secretary of EURETINA.

Prof. Anat Loewenstein discloses: Advisory role with Allergan, Bayer, BeyeOnics, Notal Vision, Novartis, Pres-By, Roche and Syneos Health. Research funding from Allergan, Bayer and Novartis.

  • Part 2: Expert Interviews
Leave Feedback
Prof. Pravin Dugel
Watch Time: 04:21
Roski Eye Institute, Keck School of Medicine, University of Southern California, CA, USA

Prof. Pravin Dugel, Clinical Professor at the Roski Eye Institute, University of Southern California, USA, provides his expert insight into key data presented at EURETINA 2019 and discusses what the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.

 
Leave Feedback
Interview Questions

In this interview, Pravin Dugel answers the following quesitons:

  • Why retinal fluid is important as a marker of disease activity in patients with nAMD. Focus on the rationale for and evidence to support using retinal fluid as a marker?
  • How can the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes?
  • Potential benefits of a smaller-size anti-VEGF therapy on dosing. Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes?
About Prof. Pravin Dugel

Prof. Pravin Dugel joined Retinal Consultants of Arizona in July 1994 and is currently Managing Partner, Retinal Consultants of Arizona and Clinical Professor, Roski Eye Institute, Keck School of Medicine, University of Southern California, USA. Prof. Dugel is internationally recognized as a major clinical researcher and has been a primary investigator in over 100 multicentre clinical trials. His research and educational contributions have earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO).

Prof. Pravin Dugel discloses:  Advisory board member for Acucela, Aerpio, Alcon Pharmaceutical, Alcon Surgical (RACII), Alimera Sciences, AMO, Annidis, ArticDX, ASRS Board, Avalanche, Bausch, Beyeonics, CDR-Life Inc., Clearside Biomedical, Digisight, DOSE Medical, Euretina Board, Gemini Pharmaceutical, Genentech, Graybug Vision, Lutronic, LUX BioScience, MacuSight, NeoVista, Neurotech, Novartis, Oculis, Omeros, Opthea, Ophthotech, Orbis International, Oxurion, Regenxbio, Reneuron, Retina World Congress, Roche, Santen, Shire Human Genetics, Stealth Biotherapeutics, Thrombogenics and TrueVision.  Consultant for Abfero, Acucela, Aerie Pharmaceutical, Aerpio, Alcon Pharmaceutical, Alcon Surgical, Allergan, Alimera Sciences, Amgen, Annidis, ArticDX, Arctic Vision, AsclepiX Therapeutics Inc., Bausch & Lomb Pharma, BeyeOnics, BioBridge/Retinagenix, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Daiichi Sankyo, DigiSight, DOSE Medical, Fox Kiser, Gemini Pharmaceutical, Genentech, Glaukos, Graybug Vision, Kodiak Sciences, Irenix, jCyte, Ionis, Lutronic, LUX BioScience, MacuSight, Merck, Nan Fung Group, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Opthea, Ophthotech, Optovue, ORA, PanOptica, Pentavision, Pieris Pharmaceutical, pSiveda/Eyepoint, RegenexBio, Reneuron. Roche, Santen, Inc., SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenics, TopCon and Zeiss Group.  Minor stockholder with Aerpio, Allegro, ArctixDx, Arctic Vision, Clearside Biomedical, Digisight/Verana, Fox Kiser, Graybug, Irenix, Nan Fung Group, Oculis, Ophthotech, PanOptica, SciFluor and TrueVision.

Prof. Eric Souied
Watch Time: 04:22
Hôpital Henri-Mondor’, Créteil, France

Prof. Eric Souied, Head of the Departments of Ophthalmology at the ‘Hôpital Centre Intercommunal de Créteil’ and the ‘Hôpital Henri-Mondor’, Créteil, France, provides his expert insight into key data presented at EURETINA 2019 and discusses what the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.

 
 
Leave Feedback
Interview Questions

In this interview, Eric Souied answers the following questions:

  • Why retinal fluid is important as a marker of disease activity in patients with nAMD. Focus on the rationale for and evidence to support using retinal fluid as a marker?
  • How can the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes?
  • Potential benefits of a smaller-size anti-VEGF therapy on dosing. Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes?
About Prof. Eric Souied

Prof. Eric Souied, Head of the Department of Ophthalmology at the ‘Hôpital Centre Intercommunal de Créteil’ (CHI Créteil) and the Ophthalmology Department at ‘Hôpital Henri-Mondor’, Créteil, France. He has contributed to more than 180 peer-reviewed articles published in the areas of age-related macular degeneration (AMD), hereditary retinal diseases, ophthalmic genetics and gene therapy of retinal dystrophies. His main area of research is focusing on the genetics, imaging and treatment of AMD. Professor Souied is a member of the Macula Society, Gonin Club, American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology.

Prof. Eric Souied discloses:  Advisory role with Allergan, Bayer, Novartis and Roche.

Prof. Anat Loewenstein
Watch Time: 04:16
Tel Aviv Medical Centre and Tel Aviv University, Israel

Prof. Anat Loewenstein, Chair of the Department of Ophthalmology, Tel Aviv Medical Centre and Professor of Ophthalmology and Vice Dean, Tel Aviv University, provides her expert insight into key data presented at EURETINA 2019 and discusses what the latest developments in imaging and anti-VEGF agents mean for optimizing outcomes for patients with nAMD.

 
 
Leave Feedback
Interview Questions

In this interview, Anat Loewenstein answers the following questions:

  • Why retinal fluid is important as a marker of disease activity in patients with nAMD. Focus on the rationale for and evidence to support using retinal fluid as a marker?
  • How can the burden of nAMD be reduced, and patient adherence and QoL improved? Focus on treatment regimens that improve patient outcomes?
  • Potential benefits of a smaller-size anti-VEGF therapy on dosing. Focus on how the dosing benefits of smaller-sized anti-VEGF therapies may impact clinical outcomes?
About Prof. Anat Loewenstein

Prof. Anat Loewenstein is the Chair of the Department of Ophthalmology, Tel Aviv Medical Centre and Professor of Ophthalmology and Vice Dean, Tel Aviv University. An expert in retinal toxicity with a strong research interest in the early detection of retinal disease, Prof. Loewenstein has served as the principal investigator of many clinical trials of anti-VEGF agents and steroid implants for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Prof. Loewenstein is currently the General Secretary of EURETINA.

Prof. Anat Loewenstein discloses:  Advisory role with Allergan, Bayer, BeyeOnics, Notal Vision, Novartis, Pres-By, Roche and Syneos Health. Research funding from Allergan, Bayer and Novartis.

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the latest developments in the management and treatment of patients with nAMD with our expert summary from the 19th EURETINA Congress in Paris, France, 5–8 September 2019.

Prof. Anat Loewenstein of the Tel Aviv Medical Center reviews the most important emerging data presented at the 19th EURETINA Congress and discusses their potential impact for addressing real-life clinical unmet needs in nAMD.

The information in this activity is intended for retina specialists and other healthcare professionals involved in the treatment of patients with nAMD.

Learning Objectives

After watching this touchCONGRESS, you should be able to:

  • Illustrate how retinal fluid may be used as a marker of disease activity and to guide individualized therapeutic strategy
  • Define the importance of patient adherence to treatment on clinical outcomes and the factors that impact adherence and QoL
  • Explain how smaller sized anti-VEGF antibodies may address the real-life unmet needs and confer clinical benefits

This content is for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72